Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J Glover

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017

English

Related publications

FKB327, an Adalimumab Biosimilar, Versus the Reference Product: Results of a Randomized, Phase III, Double-Blind Study, and Its Open-Label Extension

Arthritis Research & Therapy

2019

English

Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)

2019

English

Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis

Clinical Rheumatology

Medicine

Rheumatology

2019

English

Comparative Clinical Efficacy and Safety of the Proposed Biosimilar ABP 710 With Infliximab Reference Product in Patients With Rheumatoid Arthritis

Arthritis Research & Therapy

2020

English

A Phase III Randomized Study to Evaluate the Efficacy and Safety of CT-P13 Compared With Reference Infliximab in Patients With Active Rheumatoid Arthritis: 54-Week Results From the PLANETRA Study

Arthritis Research & Therapy

2016

English

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

2018

English

Rheumatoid Arthritis-Associated Uveitis Treated With Adalimumab

English

Safety and Effectiveness of Adalimumab in Patients With Rheumatoid Arthritis Over 5 Years of Therapy in a Phase 3b and Subsequent Postmarketing Observational Study

Arthritis Research and Therapy

English

Adalimumab Discontinuation in Patients With Rheumatoid Arthritis After Achieving Sustained Remission

Nauchno-Prakticheskaya Revmatologiya

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J Glover

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

Related publications

FKB327, an Adalimumab Biosimilar, Versus the Reference Product: Results of a Randomized, Phase III, Double-Blind Study, and Its Open-Label Extension

Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)

Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis

Comparative Clinical Efficacy and Safety of the Proposed Biosimilar ABP 710 With Infliximab Reference Product in Patients With Rheumatoid Arthritis

A Phase III Randomized Study to Evaluate the Efficacy and Safety of CT-P13 Compared With Reference Infliximab in Patients With Active Rheumatoid Arthritis: 54-Week Results From the PLANETRA Study

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

Rheumatoid Arthritis-Associated Uveitis Treated With Adalimumab

Safety and Effectiveness of Adalimumab in Patients With Rheumatoid Arthritis Over 5 Years of Therapy in a Phase 3b and Subsequent Postmarketing Observational Study

Adalimumab Discontinuation in Patients With Rheumatoid Arthritis After Achieving Sustained Remission